CHRONIC spontaneous urticaria (CSU) is a distressing inflammatory skin condition characterised by the recurrent appearance of hives, angioedema, or both, lasting more than six weeks without an ...

Rilzabrutinib significantly alleviates itch and hives in patients with CSU unresponsive to H1-antihistamines, offering a potential new treatment option. The RILECSU trial demonstrated significant ...

Rilzabrutinib, an oral inhibitor of Bruton tyrosine kinase (BTK), demonstrated a rapid and substantial alleviation of symptoms in patients with chronic spontaneous urticaria (CSU) unresponsive to ...

Immunology pipeline: New data from Sanofi’s immunology pipeline will be featured, including new analyses evaluating rilzabrutinib in moderate-to-severe asthma, and transcriptomic data in patients with ...

Following a period of stability in the US biologic asthma market, new data reveals hidden opportunities for differentiation and growing prescriber interest in emerging pipeline therapiesEXTON, PA, May ...

Among the candidates generating the most enthusiasm are Sanofi’s assets—amlitelimab (BTK inhibitor), lunsekimig (IL-13xTSLP Nanobody VHH), and oral rilzabrutinib (OX40L mAb)—which physicians ...

Sanofi has not had the success it was hoping for with its oral BTK inhibitors, acquired as part of its $3.7 billion buyout of Principia Biopharma, but can now point to a win for rilzabrutinib in ...

already a $12 billion blockbuster in other indications – as well as Sanofi’s rival oral BTK inhibitor rilzabrutinib, which showed promise in a mid-stage trial and is heading for phase 3 trials ...

Regulatory applications seeking approval for tolebrutinib for non-relapsing secondary progressive multiple sclerosis or nrSPMS and rilzabrutinib for immune thrombocytopenia are under review in the ...

Regulatory applications seeking approval for tolebrutinib for non-relapsing secondary progressive multiple sclerosis or nrSPMS and rilzabrutinib for immune thrombocytopenia are under review in the ...